PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.49%
R&D reduction while AGEN shows 6.01% growth. Joel Greenblatt would examine competitive risk.
-24.67%
G&A reduction while AGEN shows 33.75% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.97%
Operating expenses reduction while AGEN shows 33.75% growth. Joel Greenblatt would examine advantage.
-17.97%
Total costs reduction while AGEN shows 13.63% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.31%
EBITDA growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
17.97%
Operating income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
184.62%
Other expenses growth above 1.5x AGEN's 15.93%. Michael Burry would check for concerning trends.
18.43%
Pre-tax income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.43%
Net income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
58.16%
EPS growth exceeding 1.5x AGEN's 8.93%. David Dodd would verify competitive advantages.
58.16%
Diluted EPS growth exceeding 1.5x AGEN's 8.93%. David Dodd would verify competitive advantages.
96.23%
Share count reduction below 50% of AGEN's 16.59%. Michael Burry would check for concerns.
96.23%
Diluted share reduction below 50% of AGEN's 16.59%. Michael Burry would check for concerns.